Breast cancer relapse often begins long before it can be seen. 

Understanding how cells decide their fate is a central challenge in biology, complicated by the fact that single-cell RNA sequencing captures only static snapshots of highly complex and dynamic changes in cell state. In a recent study, researchers from Japan developed a computational method, called ddHodge, that can accurately reconstruct cell state dynamics, shedding light on how genes drive cell fate decisions. Their technique could be useful in developmental biology, regenerative medicine, and cancer research.

Dlc1 deletion affects cardiac differentiation in mouse embryonic stem cells by activating the canonical Wnt pathway

Cardiomyocyte differentiation is an important event during heart development that involves the specification of cardiac lineage cells differentiated from mesendoderm to cardiac mesoderm. This specification is spatio-temporally regulated by multiple genes and signaling pathways.

Previous studies have shown that deleted in liver cancer 1 (DLC1), a tumor-suppressor gene, is involved in embryonic development, and its knockdown leads to the malformation of multiple organs, including abnormalities in cardiovascular system development and early fatalities.

Pediatric acute megakaryoblastic leukemia (pAMKL) remains one of the most treatment-refractory forms of childhood AML, especially in cases harboring the CBFA2T3-GLIS2 (C/G) fusion. Despite the recognition of C/G as a defining oncogenic driver, the mechanisms by which it alters chromatin structure, epigenetic regulation, and transcriptional programs have not been fully understood

A new international study led by the Gray Faculty of Medical & Health Sciences at Tel Aviv University finds: melanoma cancer cells paralyze immune cells by secreting extracellular vesicles (EVs), which are tiny, bubble-shaped containers secreted from a given cell. The research team believes that this discovery has far-reaching implications for possible treatments for the deadliest form of skin cancer.

Platinum-resistant recurrent epithelial ovarian cancer carries a bleak prognosis, with single-agent chemotherapy yielding response rates below 20% and median progression-free survival barely reaching 4 months; the A-Plus phase II trial therefore tested a chemotherapy-free, all-oral regimen combining albumin-bound paclitaxel and the multi-kinase inhibitor anlotinib in 44 heavily pre-treated women. Between January 2021 and March 2023, patients aged 32-70 years received nab-paclitaxel 260 mg m⁻² intravenously on day 1 plus anlotinib 12 mg orally once daily on days 1-14 of each 21-day cycle until progression or intolerable toxicity. Eligibility required documented platinum resistance, ECOG performance status 0-1, measurable or evaluable disease by RECIST 1.1 or Rustin criteria, and adequate organ function; prior anti-angiogenic therapy or PARP inhibitors was allowed, reflecting real-world refractory populations.